Showing posts with label ASCO19. Show all posts
Showing posts with label ASCO19. Show all posts

Wednesday, June 5, 2019

Gyn Cancer Education Sessions at #ASCO19

Here is a short summary( Tweets) and notes from the Gyn Cancer Education Sessions I attended at this year's ASCO Annual Meeting. Please note these sessions were not necessarily only ovarian cancer sessions.
Abstracts are available online at https://abstracts.asco.org/239/IndexView_239.html

6/1/2019 Pharma to Table
Levinson  - Immunotherapy in Gyn Cancers


Rubin- Recognizing and Managing Immun-related Toxicities
irAE = immun-related Adverse Events
Events could include - cough, colitis, endocrine issues, pneumonitis
With adverse events is was recommended to not reduce the dose but rather hold the dose

Moore - Response Predictions and Signatures for Immuntherapy
Tumor Burden is number of mutations in a tumor.


Dorigo - The Future of Immunotherapy in Gyn Cancers
TIL - Tumor Infiltrating Lymphocytes
Trials ongoing with HPV positive ovarian cancer ( yes , HPV can cause more than cervical and head and neck cancers. ) , CAR-T cells and vaccines
Trials like this one opening soon.
6/2/2019 Are We Hitting the Bull's -eye with Targeted Therapy
Clinical Science Symposium
This session reviewed a number of Abstracts.
Abstract 5509 - Sex hormone, Insulin and insulin-like growth factors in High stage endometrial cancers
Drs Huang, Bae-Jump


Abstract 5010 - Phase 2 trial ribociclib and letrozole in ER positive ovarian and endometrial cancers Drs  Colon-Otero and Mackay


Abstract 5011 - Phase 2 avelumab plus entinostat or placebo in epithelial ovarian cancer
Drs. Cadoo and Hays



6/2/2019 Wanna Get Away - Continuous treatment vs Treatment Holidays in Gyn Cancers
Dr Buckanovich - Successful Maintenance?

Dr  Oza - Maintenance Standard of Care


 Dr Rustin - Maintenance - Not Ready for Prime Time

Dr. Trent - Sarcoma Perspective

6/2/2019 Gyn Cancers is it Time to Put Away the Knife? 
For this session I did not have a good view of the screen so here are the high points from my notes.

Dr. Duska  - Adv OC -Time to Put Away the Knife?
NACT ( Neoadjuvent chemotherapy) is a viable option for a certain population of patients with ovarian cancer

Dr Pfisterer  We need a sharper smarter knife
Residual Tumor is an independent prognostic indicator. The Goal is R0 ( no visible disease left) . What prevents R0 . Factors that influence R0 are Inoperability (sugery not tolerated), Insufficiency (surgeon not capable of performing surgery . Patient survival better when surgery is done by a gyn onc.) Irresectability ( surgery not possible due to location of tumor.)

Dr Ramirez Has Laparoscopy Sung its Final Song in Cervix Cancer
Reported on LACC Study (https://www.nejm.org/doi/full/10.1056/NEJMoa1806395)  Study found that radical hysterectomy by MIS (minimally invasive survery ) lead to lower rates of disease free survival compared to open hysterectomy.

Dr Boggess - There is still a Role of MIS in Cervical Cancer 

6/3/2019 The More Things Change the Ovarian Cancer Edition
Monk - Is It Time to Change Upfront Chemotherapy For Ovarian Cancer

Dr Randall HIPEC: Standard of Care or Hype



Dr. Grisham - Low Grade Ovarian Carcinoma: Fitting the Square Peg in the Round Hold



 Tomorrow  I will share information from sessions dealing with communication ( Tweets Chats & Posts and Navigating a New Cancer Diagnosis).


Dee
Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , , , , , , ,

Tuesday, June 4, 2019

Reporting On This Year's ASCO Annual Meeting

I returned recently from the ASCO 2019 Annual Meeting. This meeting was one of the best I have attended. I had the opportunity to met in person for the first time advocates, physicians and nurses I had interacted with online - Facebook or Twitter.  I also met a number of advocates and health care providers from around the world - Australia, Canada, England, and Nigeria to name a few.

Dr Dickson and I - #ASCO19
I was invited to speak during a ticketed session titled A Fireside Chat What Patients Want From Providers in Gynecologic Cancer on Saturday afternoon.  My partner was Elizabeth Dickson-Michelson, a gynecologic oncologist. I shared what the gyn cancer patient needs and how to advocate for yourself and others while Dr Dickson focused on how health care professionals could provide the services both emotional and physical that patients need. We also shared the results of two studies, The WOCC Every Women Study and the Needs of Women Treated for Ovarian Cancer : Results from a #gyncsm Chat . I am extremely appreciative of the support provided to me by Rutgers Cancer Institute of New Jersey which allowed my attendance at this meeting.

Before and after my presentation I was able to attend a number of very informative sessions in gynecologic cancer, communication and social media. If you didn't catch my live tweets from the meeting, over the next few days I will share information I learned on this blog. I will cover the Gyn Cancer Education Sessions  (Pharma to Table, Are We Hitting the Bulls Eye with Targeted Therapy,Wanna Get Away -Continuous vs Treatment Holidays, The More things Change OC Edition and Gyn Cancers: Is It Time to Put Away the Knife ) and two sessions dealing with communication ( Tweets Chats & Posts and Navigating a New Cancer Diagnosis), as well as an overview of the Gyn Cancer Oral Abstract Sessions and the Poster Discussion sessions. 

So Stand by --- or sit ---  more info is on its way.

Dee
Every Day is a Blessing!

  

Posted by at No comments:
Labels: , ,
Subscribe to: Posts (Atom)